drugset / Trial / NCT04815902
Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis
Phase 1/2
Unknown
100 enrolled
Steadman Philippon Research Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a prospective, randomized, double-blind, active control clinical trial to evaluate the safety and efficacy of a senolytic agent (Fisetin) and an anti-fibrotic agent (Losartan), used independently and in combination, to improve beneficial effect demonstrated by the active control which is to be injection of autologous bone marrow aspirate concentrate (BMAC) into an osteoarthritic knee.
Timeline
- Start
- 2021-05-18
- Primary completion
- 2025-02-01
- Completion
- 2025-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fisetin | Small molecule | 20 mg/kg | Oral |
| Subject | Losartan | Other / unclassified | 12.5 mg | Oral |